Timber pharmaceuticals regains compliance with nyse american continued listing standards

Basking ridge, nj, dec. 09, 2022 (globe newswire) -- via  newmediawire  -- timber pharmaceuticals, inc. ("timber" or the “company”) (nyse american: tmbr), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the company has received formal notice from the nyse american llc (“nyse american”) stating that the company has regained compliance with the nyse american's continued listing standards.
TMBR Ratings Summary
TMBR Quant Ranking